Global Blood Therapeutics, Inc. (NASDAQ:GBT) insider Jung Choi sold 3,000 shares of the stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $30.00, for a total transaction of $90,000.00. Following the completion of the sale, the insider now directly owns 140,055 shares in the company, valued at $4,201,650. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Jung Choi also recently made the following trade(s):

  • On Thursday, August 31st, Jung Choi sold 3,000 shares of Global Blood Therapeutics stock. The shares were sold at an average price of $30.00, for a total transaction of $90,000.00.
  • On Friday, July 21st, Jung Choi sold 3,000 shares of Global Blood Therapeutics stock. The shares were sold at an average price of $30.00, for a total transaction of $90,000.00.

Shares of Global Blood Therapeutics, Inc. (NASDAQ GBT) opened at 29.70 on Wednesday. The company’s 50-day moving average is $28.26 and its 200 day moving average is $29.61. Global Blood Therapeutics, Inc. has a 52 week low of $13.35 and a 52 week high of $41.15. The firm’s market capitalization is $1.30 billion.

Global Blood Therapeutics (NASDAQ:GBT) last announced its quarterly earnings data on Monday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.61) by $0.06. During the same period in the prior year, the firm earned ($0.58) EPS. Analysts anticipate that Global Blood Therapeutics, Inc. will post ($2.44) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Jung Choi Sells 3,000 Shares of Global Blood Therapeutics, Inc. (GBT) Stock” was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/jung-choi-sells-3000-shares-of-global-blood-therapeutics-inc-gbt-stock/1606782.html.

Several large investors have recently modified their holdings of the business. Morgan Stanley lifted its position in shares of Global Blood Therapeutics by 140.0% in the 1st quarter. Morgan Stanley now owns 334,872 shares of the company’s stock worth $12,340,000 after buying an additional 195,323 shares during the last quarter. Sphera Funds Management LTD. acquired a new position in shares of Global Blood Therapeutics in the 2nd quarter valued at about $4,103,000. Emory University acquired a new position in shares of Global Blood Therapeutics in the 2nd quarter valued at about $1,442,000. Marcus Capital LLC boosted its holdings in shares of Global Blood Therapeutics by 25.7% in the 2nd quarter. Marcus Capital LLC now owns 65,350 shares of the company’s stock valued at $1,787,000 after buying an additional 13,350 shares during the period. Finally, Creative Planning boosted its holdings in shares of Global Blood Therapeutics by 3,380.5% in the 2nd quarter. Creative Planning now owns 41,801 shares of the company’s stock valued at $1,143,000 after buying an additional 40,600 shares during the period. 86.07% of the stock is currently owned by institutional investors.

Several equities research analysts have recently issued reports on GBT shares. ValuEngine raised shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 10th. BidaskClub lowered Global Blood Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, June 20th. Morgan Stanley reissued an “overweight” rating on shares of Global Blood Therapeutics in a report on Tuesday, July 11th. Oppenheimer Holdings, Inc. began coverage on Global Blood Therapeutics in a research note on Friday, August 4th. They issued an “outperform” rating and a $53.00 price target on the stock. Finally, J P Morgan Chase & Co restated an “overweight” rating and issued a $46.00 price target (up from $44.00) on shares of Global Blood Therapeutics in a research note on Tuesday, August 8th. One analyst has rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $52.27.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.